Physician
Montano Wellness LLC
UConn School of Medicine, Department of Family Practice
Cromwell, Connecticut
Dr. Montano is Director and Principal Investigator for CT Clinical Research in Cromwell, Connecticut, where he also holds a private practice in internal medicine, specializing in preventative medicine and mood disorders. In addition, he is an attending physician at Middlesex Hospital in Middletown, Connecticut.
Dr. Montano received his medical degree at the Albany Medical College of Albany, New York. He completed his residency in internal medicine at St. Francis Hospital and Medical Center in Hartford, Connecticut, and then trained as a resident in neurology, gastroenterology, and dermatology at Yale University in New Haven, Connecticut.
Dr. Montano has served as principal investigator in multiple clinical trials to evaluate the safety and efficacy of novel therapeutics for major depressive disorder, fibromyalgia syndrome, and many other indications. He has authored peer-reviewed manuscripts on major depressive disorder, bipolar disorder, sleep disorders, binge-eating disorder, and especially in attention deficit hyperactivity disorder. He focuses on educating physicians and other health care workers in the area of primary care psychiatry.
AbbVie (Individual(s) Involved: Self; Clinical Condition: Psychiatry): Advisory Board, Consultant, Grant/Research Support, Speaker's Bureau; Biohaven Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Migraine): Grant/Research Support; Eisai (Individual(s) Involved: Self; Clinical Condition: Insomnia): Advisory Board, Speaker's Bureau; Eli Lilly Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Migraines): Speaker's Bureau; Idorsia (Individual(s) Involved: Self; Clinical Condition: Binge Eating Disorder): Grant/Research Support; Janssen Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Major Depressive Disorder): Grant/Research Support; Otsuka (Individual(s) Involved: Self; Clinical Condition: Psychiatry): Grant/Research Support, Speaker's Bureau; Relmada Therapeutics (Individual(s) Involved: Self; Clinical Condition: Major Depressive Disorder): Grant/Research Support; Sage Therapeutics (Individual(s) Involved: Self; Clinical Condition: Major Depressive Disorder): Grant/Research Support; Satsuma Phamaceuticals (Individual(s) Involved: Self; Clinical Condition: Migraine): Grant/Research Support; Supernus Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: ADHD): Advisory Board, Speaker's Bureau; Takeda Pharmaceuticals U.S.A. (Individual(s) Involved: Self; Clinical Condition: Psychiatry): Advisory Board, Speaker's Bureau; Tonix Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Fibromyalgia): Grant/Research Support
Wednesday, May 11, 2022
12:25 PM – 1:10 PM
Wednesday, July 20, 2022
12:20 PM – 1:05 PM
Wednesday, September 7, 2022
12:20 PM – 1:05 PM
Wednesday, November 16, 2022
12:20 PM – 1:05 PM